Cubist Systematic Strategies, LLC Taysha Gene Therapies, Inc. Transaction History

Cubist Systematic Strategies, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$1.43 - $3.25 $161,112 - $366,164	112,666 Added 232.62%	161,100 $462,000
Q4 2023 Feb 14, 2024	BUY	$1.33 - $2.88 $64,417 - $139,489	48,434 New	48,434 $85,000
Q4 2022 Feb 14, 2023	BUY	$1.39 - $2.98 $56,018 - $120,096	40,301 New	40,301 $91,000
Q2 2022 Aug 15, 2022	SELL	$2.47 - $6.77 $83,224 - $228,108	-33,694 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$5.22 - $11.86 $73,387 - $166,739	14,059 Added 71.6%	33,694 $220,000
Q4 2021 Feb 14, 2022	BUY	$11.43 - $19.2 $224,428 - $376,992	19,635 New	19,635 $229,000
Q1 2021 May 17, 2021	SELL	$20.3 - $31.75 $90,395 - $141,382	-4,453 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$19.14 - $28.13 $85,230 - $125,262	4,453 New	4,453 $118,000

117

136M

25.9K

24K

Ticker TSHA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,359,500
Market Cap $85.1M
Description
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.